RFCA
TARO

R&F Capital Advisors’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

R&F Capital Advisors’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,706
Closed -$390K – 843
2016
Q4 		$390K Buy
+3,706
New +$388K 0.14% 238

Other funds holding TARO

MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FL
Fort LP Chevy Chase, Maryland $39.6M AUM 37.11% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

R&F Capital Advisors's TARO Position: Q1 2017 in Review

R&F Capital Advisors sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q1 2017, closing a stake of 3,706 shares — an estimated $390K sold.

R&F Capital Advisors first reported a position in TARO in Q4 2016 and held it in 1 quarter. The position peaked at $390K in Q4 2016. 139 funds tracked by Wall St. Rank hold TARO as of Q1 2017.

  • R&F Capital Advisors reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 3,706 Taro Pharmaceutical Industries Ltd. shares in Q1 2017, an estimated $390K.
  • R&F Capital Advisors first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Taro Pharmaceutical Industries Ltd. position peaked at $390K in Q4 2016.
  • 139 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.